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Abstract 
Prostate cancer tissue is composed of both cancer cells and host cells. The milieu of host components that compose 
the tumor is termed the tumor microenvironment (TME). Host cells can be those derived from the tissue in which 
the tumor originates (e.g., fibroblasts and endothelial cells) or those recruited, through chemotactic or other factors, 
to the tumor (e.g., circulating immune cells). Some immune cells are key players in the TME and represent a large 
proportion of non-tumor cells found within the tumor. Immune cells can have both anti-tumor and pro-tumor activ-
ity. In addition, crosstalk between prostate cancer cells and immune cells affects immune cell functions. In this review, 
we focus on immune cells and cytokines that contribute to tumor progression. We discuss T-regulatory and T helper 
17 cells and macrophages as key modulators in prostate cancer progression. In addition, we discuss the roles of 
interleukin-6 and receptor activator of nuclear factor kappa-B ligand in modulating prostate cancer progression. This 
review highlights the concept that immune cells and cytokines offer a potentially promising target for prostate cancer 
therapy.
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Background
Prostate cancer tissues are composed of both tumor cells 
and host components. Host components consist of solu-
ble factors (e.g., cytokines), stromal matrix, and cells. The 
milieu of host components in the tumor is termed the 
tumor microenvironment (TME) [1]. The cellular com-
ponent of the TME consists of both host cells that are 
initially presented in a primary or metastatic lesion and 
cells that are recruited in response to either tumor- or 
host-derived factors. Most host cells, including stromal 
cells, vascular cells, and immune cells, may contribute to 
the function of the TME. Most cancer therapies directly 
target tumor cells through cytostatic or cytocidal activ-
ity. Recently, in addition to strategies targeting tumor 
cells, strategies targeting the TME have been explored. 
For example, it has been demonstrated that targeting 
the vasculature can reduce tumor-associated immuno-
suppression and thus improve therapeutic effects [2]. 
Accordingly, a thorough understanding of the TME is 
necessary to develop the most efficacious therapy.
Crosstalk between tumor cells and the TME results 
in an orchestrated evolution of both the TME and the 
tumor as the tumor progresses. The TME reacts to pros-
tate cancer cell-produced soluble factors and directly 
interacts with prostate cancer cells. In return, the TME 
produces soluble factors, provides structural support, 
and contacts with cancer cells to influence the establish-
ment and progression of prostate cancer [3]. There are 
several excellent reviews on tumor-TME crosstalk [4, 5]. 
In the current review, we focus on the immune compo-
nent of the TME that promotes tumor progression.
Inflammatory immune cells
Inflammation can potentially contribute to prostate 
cancer pathophysiology through several mechanisms, 
including generation of reactive oxygen species that 
lead to mutagenesis; production of cytokines to pro-
mote tumor growth and suppress anti-tumor immune 
response; and enhancement of the migration of tumor-
promoting immune cells into the tumor [6, 7]. Immune 
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cells compose the cellular arm of the inflammatory 
response, and in this review, we highlight some of these 
cells and how they have been thought to contribute to 
prostate cancer progression (Table 1).
Tumor‑modulating T cells and prostate cancer
Tumor-infiltrating lymphocytes (TILs) contribute to the 
progression of prostate cancer through multiple mecha-
nisms that have not been well defined yet. One type of 
TIL, the T-regulatory cell (Treg), has been identified 
as a primary mediator in cancer progression. Tregs are 
CD4+ T cells that inhibit the activity of T effector cells; 
however, specific definitions based on cell surface mark-
ers constantly change due to heterogeneity of the Treg 
population [8]. This constant evolution of defining the 
Treg phenotype creates a challenge in interpreting the lit-
erature, and one must be aware of how the Treg is defined 
in a particular publication. Tregs tend to suppress anti-
tumor responses rather than promote tumor cell growth 
directly. In support of the importance of Tregs in prostate 
cancer, Tregs that were defined as CD4+CD25high cells 
with in  vitro immunosuppressive function were found 
to be increased in prostate cancer tissues compared with 
non-cancerous prostate tissues [9]. In addition, to deter-
mine the phenotype of TILs, Sfanos et al. [10] performed 
multiple biopsies of prostate cancers and determined the 
phenotypes of the procured cells by flow cytometry. They 
found that tumor-infiltrating CD4+ T cells were skewed 
toward Treg (FoxP3+, forkhead box P3) and T helper 17 
(Th17) phenotypes rather than Th2 phenotype. This find-
ing was extended to the peripheral blood, where the pro-
portions of CD4+CD25high Tregs were increased in men 
with prostate cancer compared with healthy donors [9]. 
Further studies showed that tumor-infiltrating Tregs, 
defined as CD8+ FoxP3+ cells, suppressed naive T cell 
proliferation mainly through a cell contact-dependent 
mechanism [11]. However, the ability to suppress T-cell 
proliferation may not always result in inhibition of tumor-
specific immune activity. In a transgenic adenocarcinoma 
mouse prostate (TRAMP) model of prostate cancer, 
CD4+CD25+FoxP3+ Tregs were found to be dispensable 
for induction of tumor-specific tolerance [12]. Yokokawa 
et al. [13] evaluated levels of CD4+CD25highFoxP3+ Tregs 
in the peripheral blood of healthy donors and patients 
with biochemically progressive, localized, or metastatic 
prostate cancer by flow cytometry. The function of Tregs 
was determined by their ability to suppress the prolifera-
tion of CD4+CD25− T cells [13]. They found that although 
no differences were observed in the amount of Tregs in 
the peripheral blood among different groups, Tregs from 
patients with prostate cancer had significantly greater 
suppressive function than Tregs from healthy donors [13]. 
In addition to the tumor itself, cancer therapies may also 
affect Treg functions. For example, androgen modula-
tion is an important and often-used therapy for prostate 
cancer. In a mouse model, androgen ablation induced a 
transient increase of CD4+ T cells and CD8+ T cells in 
residual tumor [14]. More than 2  months later, FoxP3+ 
Tregs were increasingly found within prostate epithelium, 
whereas cytotoxic T lymphocytes, which were evenly dis-
tributed before androgen ablation, became sequestered 
within stroma [14]. Thus, androgen modulation could 
affect the efficacy of an immunotherapy regimen and 
should be considered when patients with prostate can-
cer are treated with immune-dependent regimens. Taken 
together, these results indicate tumors and tumor thera-
pies can affect Treg function; however, large clinical trials 
to validate these findings should be performed.
In addition to Tregs, another subset of CD4+ T cells, 
Th17 cells, may affect prostate cancer biology and 
Table 1 Summary of key immune cells and cytokines found in the tumor microenvironment of prostate cancer
CCL2 chemokine (C–C motif ) ligand-2, IL-6 interleukin-6, IL-17 interleukin-17, RANKL receptor activator of nuclear factor kappa-B ligand, Th17 T helper 17, Treg 
T-regulatory cell, TME tumor microenvironment, FoxP3 forkhead box P3
Type Prevalence and function References
Treg Definition is constantly refined; however, FoxP3 is consistently expressed. Highly prevalent in prostate cancer tissues. 
Potential roles include immunosuppression, allowing tumors to escape from immunosurveillance
[9, 11, 13, 84]
Th17 cells CD4+ T cells that express high levels of IL-17. The number of Th17 cells in tumors inversely associates with tumor 
grade, and the number of Th17 cells in peripheral blood inversely correlates with time to progression in patients with 
prostate cancer
[10, 17, 18]
Macrophages Recruited to tumors by chemotactic factors such as CCL2. Produce a variety of pro-inflammatory factors that promote 
angiogenesis and tumor growth. The increased amount of tumor-infiltrating macrophages directly associates with an 
unfavorable prognosis
[85–88]
IL-6 A pro-inflammatory cytokine. Elevated levels of IL-6 are associated with prostate cancer biochemical recurrence. Pro-
mote prostate cancer cell growth in vitro and in vivo
[40, 42, 54]
RANKL Produced by activated T cells and osteocytes. Target dendritic cells to promote antigen presentation. Tumors can 
directly produce RANKL or induce RANKL expression from the TME, resulting in osteoclastogenesis and tumor-
induced bone resorption
[58, 60, 72, 83]
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responses to immunotherapy. Th17 cells are CD4+ T 
effector cells that produce a large amount of interleu-
kin-17 (IL-17) which is a pro-inflammatory cytokine that 
attracts and activates granulocytes and monocytes [15]. 
The role of Th17 cells in cancer is controversial. They 
have been reported to both inhibit cancer and promote it 
[16]. An initial clue to the importance of Th17 cells came 
from an early study which demonstrated that injection of 
a fusogenic glycoprotein in combination with heat shock 
protein 70 (HSP70), as an immune adjuvant, induced 
an anti-tumor T-cell immune response that was associ-
ated with increased IL-17 expression [17]. To compare 
the prognostic implications of the pretreatment level of 
Th17 cells with those of Tregs in prostate cancer patients 
who received active whole-cell vaccine-based immuno-
therapy, Derhovanessian et al. [18] detected the frequen-
cies of Th17 cells and Tregs in the peripheral blood of 
patients with hormone-resistant non-bone metastatic 
prostate cancer prior to immunotherapy. They found 
that the frequency of Th17 cells inversely correlated with 
time to disease progression. Furthermore, patients who 
responded to immunotherapy with significant reduc-
tions in prostate-specific antigen (PSA) velocity showed 
a Th17 profile similar to that of healthy men; whereas, 
those who did not respond had a significantly differ-
ent Th17 profile compared with that of responders and 
healthy men [18]. In contrast, although the frequency 
of Tregs in the peripheral blood was higher in men with 
prostate cancer than in age-matched healthy men, no 
difference was observed between responders and non-
responders [18]. These data indicated that Th17 cells may 
predict therapeutic response to active whole-cell vaccine-
based immunotherapy. The true role that Th17 cells play 
in prostate cancer (i.e., inhibit or promote prostate can-
cer progression) may depend on tumor stage. Additional 
research efforts should be devoted to this concept.
Macrophages and prostate cancer
Macrophages have been found to play intriguing roles 
in promoting tumor progression. Among bone marrow-
derived cells in the TME, macrophages are one type of 
these cells that significantly associate with tumor pro-
gression and immunosuppression [19–23]. It has been 
well recognized that macrophages infiltrate the tumor 
tissue (these macrophages are termed tumor-associated 
macrophages [TAMs]); moreover, for prostate cancer, 
more macrophages were observed in metastatic nod-
ules than in primary tumors [24]. The increase of TAMs 
in prostate cancers may be mediated through prostate 
cancer-derived parathyroid hormone-related protein 
(PTHrP) which has been shown to recruit myeloid cells 
via osteoblast-produced chemokine (C–C motif ) ligand 2 
(CCL2) [25]. Although an increase of TAMs in prostate 
cancers is well recognized, little is known about the spe-
cific mechanisms by which macrophages promote tumor 
growth.
A primary role of macrophages is phagocytosis during 
bacterial infection [26], yet phagocytosis is an often over-
looked function relative to tumorigenesis [27, 28]. Effe-
rocytosis refers to the specific phagocytosis of apoptotic 
cells and is an integral process in tissue homeostasis, 
inflammation, and autoimmunity [29]. Like many other 
tumor-promoting activities, efferocytosis is a physiologic 
activity that may be hijacked by tumors to benefit their 
establishment and growth.
Macrophages perform efferocytosis via distinct recep-
tor signaling pathways [30]. Specific “eat me” signal 
molecules, such as milk fat globule-E8 (MFG-E8), are 
expressed by activated macrophages and bridge apoptotic 
cells and macrophages to facilitate efferocytosis [31–33]. 
MFG-E8 includes the N-terminus that bears a signal 
peptide to direct secretion, an epidermal growth factor 
(EGF)-repeated domain that contains an Arg-Gly-Asp 
(RGD) motif for recognition of integrin on phagocytic 
cells, and the C-terminus that bears a factor V/VIII-like 
domain enabling binding to phosphatidylserine in apop-
totic cells [33]. MFG-E8 is produced by several types of 
cells, most notably macrophages, and co-localizes with 
the activated marker CD68 [34]. The majority of research 
on MFG-E8 has been performed in the mammary gland, 
where it was originally identified, as well as in the perito-
neal cavity, spleen, and lung [34]. In patients with triple-
negative breast cancer, MFG-E8 promotes breast cancer 
progression through the p63 pathway; but in estrogen 
receptor- and erbB2-positive breast cancers, MFG-E8 
serves a suppressive function [35]. In the context of pros-
tate cancer bone metastasis, TAMs are polarized upon 
interaction with apoptotic tumor cells in an MFG-E8-de-
pendent manner that supports tumor progression [36], 
similar to that observed in triple-negative breast cancer 
[35]. In the bone microenvironment, factors released by 
efferocytic macrophages could increase the resistance of 
bone metastases to cancer therapies, resulting in a lack 
of therapeutic response or reduced response duration. 
MFG-E8 and other intra- and extra-cellular signaling 
events specifically related to macrophage-mediated effe-
rocytosis represent intriguing new pharmacologic targets 
for patients with bone metastasis.
Cytokines and prostate cancer
A variety of cytokines are secreted by cells in the TME 
that can affect prostate cancer growth. These cytokines 
can act in a paracrine fashion on tumor cells to stimu-
late a variety of tumor activities, including proliferation, 
chemoresistance, anti-apoptosis, migration, and inva-
sion. In this review, we focus on two immune-related 
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cytokines, interleukin-6 (IL-6) and receptor activa-
tor of nuclear factor kappa-B ligand (RANKL), that are 
expressed in the TME of prostate cancer.
IL‑6
IL-6 is produced by inflammatory cells and osteoblasts 
and has ample opportunities to interact with prostate 
cancer cells [37]. A great deal of clinical and experimen-
tal evidence suggests that IL-6 promotes prostate cancer 
progression [38]. Several studies have shown that IL-6 
level is elevated in the sera of patients with metastatic 
prostate cancer [39–41]. For example, Alcover et al. [40] 
assessed serum levels of IL-6 and its soluble receptor to 
determine if these levels could be used to predict bio-
chemical recurrence in patients who underwent radical 
prostatectomy. They found that preoperative serum lev-
els of IL-6 higher than 1.2  pg/mL in men with prostate 
cancer were associated with an increased probability of 
biochemical recurrence (i.e., increased serum PSA lev-
els) [40]. Although the study had a small sample size, the 
results support further evaluation of IL-6 as a prognostic 
factor. Similarly, Stark et al. [41] proved that pre-diagnos-
tic IL-6 level was associated with time to progression/
death for prostate cancer patients with healthy weight. 
Overall, the preponderance of evidence suggests that 
IL-6 level is elevated in men with prostate cancer and is 
related to the clinical outcome of prostate cancer.
In addition to these clinical observations, in vitro cel-
lular studies have shown that IL-6 modulates the growth 
of prostate cancer cells. Chung et  al. [42] showed that 
IL-6 promoted the growth of hormone-refractory cells 
but had no effect on hormone-dependent cell lines. Some 
studies have reported that the addition of exogenous 
IL-6 to the culture media of prostate cancer LNCaP cells 
resulted in a dose-dependent growth inhibition with neu-
roendocrine differentiation [43, 44], whereas in other 
instances, cell proliferation was increased [42–48]. The 
reasons for these differences have not yet been clarified, 
and it appeared that IL-6 inhibited the growth of only 
LNCaP cells but not other prostate cancer cell lines [49].
In addition to increased proliferation, decreased apop-
tosis can also promote tumor growth. IL-6 has an anti-
apoptotic effect on many types of cancer cells, including 
prostate cancer cells [50, 51]. A previous study demon-
strated that orchiectomy induced a conversion of LuCaP 
35 tumors to an androgen-independent phenotype 
through increased IL-6 expression [52]. It has been shown 
that targeting IL-6 with an IL-6 antibody promoted the 
apoptosis of androgen-independent PC-3 cells in mice 
[53]. IL-6 protects prostate cancer cells against apoptosis 
through activation of signal transducer and activator of 
transcription 3 (STAT3) [50] and phosphatidylinositol-3 
kinase (PI3K) [51]. Taken together, decreased prolifera-
tion and increased apoptosis caused by inhibiting IL-6 
suggest that IL-6 coordinates both processes to promote 
the growth of androgen-independent tumors.
In addition to the effect of enhancing cell prolifera-
tion, IL-6 also enhances other aspects of prostate cancer. 
For example, IL-6-mediated activation of STAT3 acti-
vates insulin-like type I growth factor receptor (IGF-IR), 
resulting in tumorigenesis [54]. IL-6 is also associated 
with neuroendocrine differentiation of prostate cancer 
cells [44]. In combination with the cytokine CCL2, IL-6 
induces M2-type macrophage polarization and promotes 
CD11b+ peripheral blood mononuclear cell survival [55]. 
Together, these findings indicate that IL-6 contributes to 
prostate cancer progression through multiple activities.
The above published studies suggesting the contribu-
tion of IL-6 to prostate cancer progression provided 
the rationale for a clinical trial to evaluate IL-6-targeted 
therapies. A human-mouse chimeric monoclonal neu-
tralizing IL-6 antibody (siltuximab, also known as CNTO 
328) has been evaluated in a phase II study in men with 
advanced castration-resistant prostate cancer, with PSA 
response rate being the primary endpoint [56]. However, 
the response rate was only 3.8%, and no men with meas-
urable disease had a response according to the Response 
Evaluation Criteria in Solid Tumors (RECIST); even 
so, C-reactive protein, an indicator of IL-6 activity, was 
decreased, suggesting that IL-6 was effectively neutral-
ized [56]. These results suggest that targeting IL-6 in men 
with advanced castration-resistant disease may not result 
in a significant direct anti-tumor benefit. In contrast to a 
direct anti-tumor effect, IL-6 has an anti-apoptotic effect 
[57], suggesting a possibility that targeting IL-6, which 
would block the anti-apoptotic effect of IL-6, may syn-
ergize with a chemotherapy regimen by promoting cell 
death.
RANKL
RANKL is expressed on the surface of activated T cells 
and interacts with its receptor, receptor activator of 
nuclear factor kappa-B (RANK), on dendritic cells (DCs) 
to promote the survival of DCs and increase their activi-
ties as antigen-presenting cells [58]. In addition to its 
direct immune function, RANKL promotes osteoclas-
togenesis. It has been identified that osteocytes also 
produce RANKL in the bone microenvironment [59]. 
RANKL can be expressed as a membrane-bound mol-
ecule or, in some instances, be cleaved to form a func-
tional soluble RANKL peptide [60]. RANKL binds to 
the transmembrane receptor RANK on osteoclast pre-
cursors and initiates osteoclastogenesis [61, 62]. It has 
been demonstrated that RANKL and RANK are required 
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for osteoclastogenesis since transgenic rankl−/− and 
rank−/− mice had no osteoclasts or developed osteo-
sclerotic bones [63, 64]. Osteoprotegrin (OPG) is a 
soluble glycoprotein that negatively regulates osteoclas-
togenesis through sequestering RANKL, resulting in the 
block of its interaction with RANK [65]. Thus, the bal-
ance between RANKL and OPG determines the extent of 
bone resorption.
Many cancers found in the skeleton [66], including 
osteoclastomas [67] and prostate cancer bone metastases 
[68], have dysregulated RANKL, OPG, or RANK expres-
sion. Both prostate cancer epithelium and stromal cells 
express RANKL [68], whose level directly associates with 
disease stage [69] and may have a prognosis-predictive 
value [70]. Prostate cancer cells initiate osteoclastogen-
esis through RANKL [71, 72]. In murine models of pros-
tate cancer bone metastasis, using OPG [71] or soluble 
RANK [73] to inhibit RANKL activity decreased both the 
amount of mature osteoclasts and the frequency of bone 
lesions. The decrease of tumor-induced bone destruction 
is associated with decreased pain-associated behaviors in 
murine models of bone cancer [74, 75]. Taken together, 
these findings suggest that inhibiting RANKL will dimin-
ish both tumor-associated bone remodeling and bone 
pain.
In addition to its effect on bone remodeling, RANKL 
has direct effects on cancer cells. For example, RANKL 
binds with RANK on prostate cancer cells and then 
induces pro-metastatic gene expression, resulting in 
increased invasive ability of prostate cancer cells [76]. 
Furthermore, inhibition of RANKL by OPG promotes 
prostate cancer cell survival through inhibition of TNF-
related apoptosis-inducing ligand (TRAIL)-mediated 
apoptosis [77]. These findings, in combination with 
the reports of tumor-mediated bone resorption via 
RANKL, indicate that targeting RANKL would have a 
two-pronged therapeutic effect by inhibiting both tumor-
induced bone resorption and pro-metastatic activity of 
tumor, which have provided the rationale to evaluate the 
clinical efficacy of targeting RANKL in cancer-related 
bone diseases.
The anti-tumor effect of denosumab, a human mono-
clonal IgG2 antibody that targets RANKL, has been 
evaluated in several clinical trials. Denosumab reduced 
the expression of urinary N-telopeptides of collagen 
(uNTx), a biomarker for osteoclast activity, in a phase II 
study that included patients with prostate cancer bone 
metastases [78]. In another clinical trial, bone mineral 
density (BMD) was significantly improved compared 
with baseline after treatment with denosumab in men 
with prostate cancer who were being treated with andro-
gen-deprivation therapy [79, 80]. Also in a clinical trial, 
zoledronic acid (an anti-osteoclastic bisphosphonate) 
was compared with denosumab for prevention of skel-
etal-related events (SREs: defined as presence of bone 
fracture, need for bone pain palliation, or need for bone 
surgery) in men with castration-resistant prostate can-
cer and bone metastases [81]. Denosumab significantly 
delayed the time to first on-study SRE as well as the time 
to first and subsequent on-study SRE compared with 
zoledronic acid [81]. The above studies and additional 
preclinical and clinical data [82, 83] have supported the 
United States Food and Drug Administration approval 
of denosumab for treating patients with prostate cancer 
(and breast cancer) bone metastases.
Conclusions and future directions
Multiple host factors in the TME contribute to prostate 
cancer progression (Fig. 1; Table 1). Immune cells, such 
as Tregs, Th17 cells, and macrophages, are major mod-
ulators of prostate cancer progression. In addition, host 
cells affect prostate cancer cells via cytokines. Cytokines 
such as IL-6 and RANKL have pleiotropic actions on 
prostate cancer cells. These findings show that the TME 
offers potentially promising targets for prostate cancer 
therapy. Further studies on host immune factors, in addi-










Fig. 1 Key immune cells and cytokines in the tumor microenviron-
ment of prostate cancer. Tregs suppress the activation of anti-tumor 
T cells to promote tumor progression. Th17 cells may promote or 
inhibit prostate cancer progression depending on the context. 
Macrophages promote prostate cancer growth through efferocytosis. 
Inflammatory stimuli can lead to IL-6 production, which, in turn, can 
promote prostate cancer growth. Prostate cancer cells can produce 
RANKL directly and stimulate host cells (e.g., osteocytes) to produce 
RANKL in the tumor microenvironment. RANKL can then mediate 
tumor-induced bone remodeling through osteoclast activation. IL-6 
interleukin-6, Mɸ macrophage, RANKL receptor activator of nuclear 
factor kappa-B ligand, Th17 T helper 17, Treg T-regulatory cell, FoxP3 
forkhead box P3
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